Organic chemist, pharmacologist, and drug designer. Exploring psychoactive substances, cognitive optimization, and harm reduction through scientific rigor and first-hand experience.
Every molecule is a hypothesis.
I have tested more than three hundred and fifty of them.
Alessio J. M. Rossini — organic chemist, pharmacologist, drug designer. Lugano, Switzerland. Born 1991.
350 compounds documented first-hand — research chemicals, novel psychoactives, nootropics, performance compounds. Not recklessness: method. Where the literature stopped, I went and found out, and then went back to the literature to understand what had happened.
My work sits where receptor pharmacology meets the thing itself. I teach all psychoactive substances without stigma and without the arbitrary lines drawn between them — a receptor does not read legislation.
My spiritual mentors: Alexander “Sasha” Shulgin, David Nutt, David E. Nichols, and Albert Hofmann — whom I had the honor of visiting in 2009 during the production of the documentary “The Substance”.
For consultations, research collaborations, or harm-reduction oriented guidance, my time is available by appointment.
Where the money is actually going, read from the pipeline rather than the headlines. Trial phases, corporate filings and the literature signal — with a pharmacologist’s note on what each one means.
Pipeline and filing data are public record. The commentary is an opinion on the science, not on any security — nothing here is investment advice.
One-to-one consultations on pharmacology, harm reduction, nootropic and performance protocols, drug design and SAR. Pick a format below — booking happens right here.
Structured archive of pharmacology, psychoactive substances, mechanisms of action, receptor profiles, and applied knowledge. Not pop-science — analysis. 2,718 compounds, interactive interaction checker, 2D structures, and a navigable taxonomy tree.
Complete receptor profiles, binding affinities, selectivity profiles, signal transduction mechanisms. Every molecule mapped to its target with Ki/EC50 data when available.
From monoamines to glutamatergic systems, sigma receptors to endogenous opioids. Structured analysis by receptor class with SAR cross-references and clinical data.
Antidepressants, anxiolytics, antipsychotics, mood stabilizers. Mechanisms, PK/PD, interactions, and real-world safety profiles — not the sugarcoated data sheets.
Racetams, cholinergic modulators, mitochondrial enhancers, eugeroic compounds. Real evidence vs. marketing. Rational stacks based on mechanism, not hype.
NPS, designer drugs, structural analogs. Pharmacological profiles, SAR, first-hand reports. Territory where peer-reviewed literature doesn't reach — and where more rigor is needed, not less.
What you won't find elsewhere. Advanced protocols, documented high-risk combinations, real toxicity mechanisms. Only for those with the background to contextualize.
AAS, peptides, SARMs, GH secretagogues. Endocrine pharmacology applied to performance enhancement. Mechanisms, protocols, side effect management.
Three decades of research chemicals — chemistry-driven exploration, commercialization, regulatory pressure, and industrialized distribution. Navigate the phases.
From local synthesis to modular global logistics. Production, conversion, and distribution geographies have fragmented and specialized over three decades.
Pharmacology without the moral costume. Essays, doctrine, and harm-reduction from the mental laboratory.
Legal/illegal is the dumbest way to understand drugs.
Prohibition did not eliminate drugs. It outsourced pharmacology to criminals.
Bad language produces bad thinking. Bad thinking produces bad policy.
Familiarity is not mastery. Survival is not competence.
An open invitation to curious minds. Draw a structure — a hypothesis, a what-if, an analogue you can’t stop thinking about — and send it my way. The canvas is Ketcher (open-source): paste a SMILES or build from scratch, then fire it off as a creative prompt.
Paste a SMILES to load it, or draw on the canvas and pull the SMILES back out. When you have something worth sharing, hit Send this structure — it opens an encrypted message, pre-filled.
Marquis, Mecke, Mandelin, Froehde, Liebermann, Ehrlich, Folin, Simon's and Scott — what each reagent actually detects, the colour transitions to expect, and the distinctions that matter in practice. Photograph a reaction and compare it against the expected palette.
A reagent test narrows down what a substance class is. It does not establish purity, dose, or the absence of an adulterant — and no colour result makes a sample safe.
229 wellness and performance peptides, opening on mass per residue — each peptide’s molecular weight divided by its residue count. The dashed line sits at ~110 Da, the average mass of an amino acid: anything above it carries mass that is not backbone, whether lipidation, conjugation, Fc fusion or other modifications. One click switches to the log-scaled residues × molecular weight scatter.
Vial content, diluent volume, requested amount — and the position to draw on the barrel in front of you, on a U-100 scale or any printed scale you define. Full decimal arithmetic, the substitution shown line by line, and a flag when the result falls between two markings instead of being quietly rounded onto one.
Concentration arithmetic only — it converts a requested amount, it does not propose one.
Technical analyses, advanced protocols, curated databases, and unreleased research. Access by invitation.
The path, unfiltered.
Visiting the discoverer of LSD during the filming of “The Substance”. An unrepeatable formative moment.
Systematic study of organic chemistry and synthesis. Early work on structure-activity relationships.
Over 200 compounds tested. Building a personal database of pharmacological profiles and subjective reports.
Launch of consulting practice. Integration of computational drug design and applied pharmacological analysis.
Launch of the digital platform. EncicloDOPEdia. Building a space where pharmacology meets operational truth.
For consultations, research, or collaborations. Private communications via encrypted channels.
Communications via ProtonMail and Telegram are end-to-end encrypted. I do not retain personal data beyond operational necessity.